Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE LY3214996 also exhibited synergistic combination benefit with a pan-RAF inhibitor in a KRAS-mutant colorectal cancer xenograft model. 31744895 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE The KRAS mutation is common in colorectal cancer, however the correlation between KRAS status and micrometastases has not been thoroughly clarified. 31720935 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer. 31782995 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE KRAS mutation and abnormal expression of Cripto-1 as two potential candidate biomarkers for detection of colorectal cancer development. 31692030 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE COX-2/C-MET/KRAS status-based prognostic nomogram for colorectal cancer: A multicenter cohort study. 30720004 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Positive concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer time period between blood and tissue sampling and was higher in colorectal cancer than in other malignancies. 31199507 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. 30737098 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS-mutated HCT116 colorectal cancer (CRC) cells. 31396956 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789 2020
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE As a result, a classification model built with methylation of SDC2 and SFRP2, KRAS mutations and hemoglobin showed a sensitivity of 91.4% for colorectal cancer and 60% for adenoma with the specificity of 86.1%. 31456088 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE In overall, besides implicating ERBB2 as an important therapeutic target under neo-adjuvant or adjuvant settings, we present the first evidence that the presence of KRAS mutations may preclude gallbladder cancer patients to respond to anti-EGFR treatment, similar to a clinical algorithm commonly practiced to opt for anti-EGFR treatment in colorectal cancer. 30304546 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE We conducted a systematic review and meta-analysis of the additive effect of biologic agents to adjuvant chemotherapy on survival in colorectal cancer (all comers and subpopulations defined by microsatellite instability, BRAF and KRAS status, and stage). 30782542 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE In this issue of <i>Cancer Discovery</i>, Poulin and colleagues apply structural, biochemical, and biological profiling of two mutants of KRAS, one found most frequently in all cancers (G12D) and one found nearly exclusively in colorectal cancer (A146T). 31160330 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE KRAS G12D point mutation plays an important role in the incidence of non-small-cell lung cancer (NSCLC) as well as colorectal cancer, pancreatic cancer and breast cancer. 30876538 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Association between KRAS G13D mutations and anastomotic recurrence in colorectal cancer: Two case reports. 30896620 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE This study included the results of KRAS mutation tests for colorectal cancer in 401 specimens. 30846412 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE A notable exception is KRAS G12C, which imparted an adverse prognosis only in colorectal cancer. 30568222 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Strategies to target energy metabolism in consensus molecular subtype 3 along with Kirsten rat sarcoma viral oncogene homolog mutations for colorectal cancer therapy. 30341899 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE However, no clinical features have been linked to KRAS mutations in colorectal cancer [CRC]. 31571990 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Our experiments highlight key differences between oncogenic BRAF and KRAS in colorectal cancer and find unexpected heterogeneity in a signalling pathway with fundamental relevance for cancer therapy. 31266962 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Prognostic impact of K-RAS mutational status and primary tumor location in patients undergoing resection for colorectal cancer liver metastases: an update. 31426677 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE In fact, the discordant pattern of BRAF and KRAS ctDNA was significantly correlated with the clinical response of melanoma to pembrolizumab treatment and progression of colorectal cancer noted by PET and/or CT scan. 31727009 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 Biomarker disease BEFREE Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. 31409052 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE The US Food and Drug Administration approved a liquid biopsy test for EGFR-activating mutations in patients with non-small-cell lung cancer as a companion diagnostic for therapy selection. ctDNA also allows for the identification of mutations selected by treatment such as EGFR T790M in non-small-cell lung cancer. ctDNA can also detect mutations such as KRAS G12V in colorectal cancer and BRAF V600E/V600K in melanoma. 30883505 2019
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
0.100 GeneticVariation disease BEFREE Our findings provide a novel explanation for the limited response to MEK inhibitors in KRAS-mutant colorectal cancer, known for its inflammatory nature. 30353166 2019